Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6831 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2024-09-25 (elpais.com)
A scientific rebellion to get Europe to approve a controversial Alzheimer’s drug
The new monoclonal antibody lecanemab has been greenlighted by the US and other countries, but the European Medicines Agency considers that the benefits do not outweigh the risks
Read more
2024-05-20 (concurrences.com)
The Italian Competition Authority launches an investigation into suspected pay-for-delay agreements between eight pharma companies concerning a biosimilar drug (Biogen / Samsung / Genentech...)
On May 21, 2024, the Italian Competition Authority (the AGCM or ICA) opened new proceedings against eight pharmaceutical companies to investigate suspected pay-for-delay practices in breach of the…
Read more
2024-02-13 (yahoo.com)
Biogen Plunges as Alzheimer Drug’s Slow Uptake Signals Reset
( Bloomberg) -- Biogen Inc. fell the most in two years as its latest foray into Alzheimer’ s disease got off to a slow start, suggesting a long road to growth for the biotechnology giant.Most Read from BloombergMusk Says Putin Can’ t Lose in Ukraine, Opposes Senate BillWall Street Caught Off Guard
Read more
2016-10-12 (nature.com)
Biosimilars in IBD: from theory to practice
Biologic agents have revolutionized the management of IBD and biosimilars (copy versions of the originator agents) are emerging as an alternative. This Review outlines the concept of biosimilars and their adoption in gastroenterology, their current use and future challenges. Biologic agents have
Read more
2011-09-06 (fiercepharma.com)
Biogen Idec Fully Acquires Biogen Dompé Joint Ventures
WESTON, Mass. & MILAN--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) today announced the company will acquire 100% of Dompé shares in its joint ventures in both Italy and Switzerland. This | WESTON, Mass.
Read more
2006-05-15 (bostonmagazine.com)
The Big Digs 2005
He's probably more of a Green Line guy: After the terrorist attacks in London, Governor Mitt Romney rides the T to demonstrate the safety of […]
Read more
Used by 100+ compliance teams and analysts